

Catenin Beta 1 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/CDF8A493760CEN.html>

Date: November 2020

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: CDF8A493760CEN

Abstracts

Catenin Beta 1 - Pipeline Review, H2 2020

SUMMARY

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or β -catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 6 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Non Malignant Disorders, Gastrointestinal and Respiratory which include indications Colorectal Cancer, Melanoma, Solid Tumor, Breast Cancer, Hepatocellular Carcinoma, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Benign Tumor, Blood Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Head And Neck Cancer, Hemangiomas,

Hematological Tumor, Hepatic (Liver) Tumor, Idiopathic Pulmonary Fibrosis, Leukemia, Liver Cirrhosis, Lung Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.

Furthermore, this report also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)

The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development

Aileron Therapeutics Inc

Circle Pharma Inc

Dicerna Pharmaceuticals Inc

Fog Pharmaceuticals Inc

iBeCa Therapeutics

MD2 Biosciences Inc

PRISM Pharma Co Ltd

Propanc Biopharma Inc

Sapience Therapeutics Inc

Sumitomo Dainippon Pharma Oncology, Inc

Venn Therapeutics LLC

WntRx Pharmaceuticals Inc

Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles

Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exisulind - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Hepatoblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRI-724 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Beta Catenin for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WX-024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products

Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones

Featured News & Press Releases

Jun 17, 2020: Sapience Therapeutics to present data on γ -catenin antagonist program at 2020 AACR Virtual Annual Meeting II

Apr 14, 2020: Propanc Biopharma receives first allowance for key patent family from Australian Patent Office

Jan 21, 2020: Propanc Biopharma receives advance overseas finding from Innovation and Science Australia

Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients

Aug 21, 2019: Propanc Biopharma receives granted US patent covering additional composition claims for PRP

Aug 12, 2019: Propanc Biopharma publishes key data in peer reviewed journal confirming anti-cancer stem cell effects of Proenzymes

Aug 08, 2019: Propanc Biopharma completes development of bio-analytical assay method to quantify PRP active ingredients in preparation for first-in-human study

Jul 15, 2019: Propanc Biopharma provides update on preparation of PRP for clinical trial application submission and recently completed reverse stock split

Jun 27, 2019: Propanc Biopharmas Intellectual Property portfolio undergoes rapid growth

May 06, 2019: Propanc Biopharma appoints Dr. Ralf Brandt to its scientific advisory board

Apr 26, 2019: Announcement of the signing of a joint R & D agreement and commencement of development activities regarding "Research and development of innovative antifibrotic drugs to improve the life prognosis of cirrhosis"

Mar 25, 2019: Propanc Biopharma initiates development of bio-analytical assay in preparation for human trials

Mar 13, 2019: Propanc Biopharma receives notice of allowance for additional claims from foundation patent in the U.S.

Dec 20, 2018: Novel development drug OP-724 (PRI-724) for the treatment of cirrhosis is published on Nature Outline

Nov 14, 2018: Adoption as a practical realization development type of the cyclic innovation for clinical empowerment by the Japan Agency for Medical Research and Development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aileron Therapeutics Inc, H2 2020
Pipeline by Circle Pharma Inc, H2 2020
Pipeline by Dicerna Pharmaceuticals Inc, H2 2020
Pipeline by Fog Pharmaceuticals Inc, H2 2020
Pipeline by iBeCa Therapeutics, H2 2020
Pipeline by MD2 Biosciences Inc, H2 2020
Pipeline by PRISM Pharma Co Ltd, H2 2020
Pipeline by Propanc Biopharma Inc, H2 2020
Pipeline by Sapience Therapeutics Inc, H2 2020
Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, H2 2020
Pipeline by Venn Therapeutics LLC, H2 2020
Pipeline by WntRx Pharmaceuticals Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Catenin Beta 1 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/CDF8A493760CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDF8A493760CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970